href="#ulink_bd261dfc-e607-5178-a835-214bb89af57a">3Weller A, O’Brien ME, Ahmed M, Popat S, Bhosle J, McDonald F, et al: Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer 2016;59:65–78.
4Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT: Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009;35:309–321.
5Serkova NJ, Eckhardt SG: Metabolic imaging to assess treatment response to cytotoxic and cytostatic agents. Front Oncol 2016;6:152.
6Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, et al: 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 2013;54:1528–1534.
7Grootjans W, de Geus-Oei LF, Troost EG, Visser EP, Oyen WJ, Bussink J: PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol 2015;12:395–407.
8Prestwich RJ, Vaidyanathan S, Scarsbrook AF: Functional imaging biomarkers: potential to guide an individualised approach to radiotherapy. Clin Oncol 2015;27:588–600.
9Croteau E, Renaud JM, Richard MA, Ruddy TD, Benard F, deKemp RA: PET metabolic biomarkers for cancer. Biomark Cancer 2016;8(suppl 2):61–69.
10Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al: Imaging tumour hypoxia with positron emission tomography. Br J Cancer 2015;112:238–250.
11Laking G, Price P: Radionuclide imaging of perfusion and hypoxia. Eur J Nucl Med Mol Imaging 2010;37(suppl 1):S20–S29.
12Wahl RL, Herman JM, Ford E: The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol 2011;21:88–100.
13O’Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, et al: Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 2017;14:169–186.
14Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ: PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011;8:233–242.
15Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.
16Hoeben BA, Bussink J, Troost EG, Oyen WJ, Kaanders JH: Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol 2013;52:1257–1271.
17Span PN, Bussink J: Biology of hypoxia. Semin Nucl Med 2015;45:101–109.
18Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J: Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674–687.
19Padhani AR, Krohn KA, Lewis JS, Alber M: Imaging oxygenation of human tumours. Eur Radiol 2007;17:861–872.
20Wouters BG, Koritzinsky M: Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8:851–864.
21Meijer TW, Kaanders JH, Span PN, Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012;18:5585–5594.
22Leszczynska KB, Foskolou IP, Abraham AG, Anbalagan S, Tellier C, Haider S, et al: Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J Clin Invest 2015;125:2385–2398.
23Wijsman R, Kaanders JH, Oyen WJ, Bussink J: Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging 2013;57:244–256.
24Yaromina A, Krause M, Baumann M: Individualization of cancer treatment from radiotherapy perspective. Mol Oncol 2012;6:211–221.
25Begg AC, Stewart FA, Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239–253.
26Hoff CM, Lassen P, Eriksen JG, Hansen HS, Specht L, Overgaard M, et al: Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? – Results from the randomized DAHANCA 5 and 7 trials. Acta Oncol 2011;50:1006–1014.
27Lambin P, Ramaekers BL, van Mastrigt GA, et al: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009;3:CD006158.
28Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al: Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012;30:1777–1783.
29Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al: Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. Clin Cancer Res 2014;20:1345–1354.
30Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135–146.
31Bussink J, van Herpen CM, Kaanders JH, Oyen WJ: PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010;11:661–669.
32Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al: PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 2014;4:365–384.
33Krohn KA, Link JM, Mason RP: Molecular imaging of hypoxia.
